NeuroOne Medical Files to Sell Up to $13.4M in Shares via ATM Program

NeuroOne Medical Technologies Corporation filed an updated Prospectus Supplement for its existing at-the-market (ATM) offering program. The filing covers the potential sale of up to $13.4 million of its common stock from time to time.

Key Details

• Offering Size: The company may offer and sell up to $13.4 million of its common stock.
• Sales Agent: JonesTrading Institutional Services LLC will continue to act as the sales agent for the offering.
• Agreement: The sales are conducted under the Capital on Demand™ Sales Agreement, originally established on December 21, 2022.
• Filing Date: The updated Prospectus Supplement was filed on June 12, 2026.